These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 29288428)

  • 1. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG.
    Scappaticci GB; Marini BL; Nachar VR; Uebel JR; Vulaj V; Crouch A; Bixby DL; Talpaz M; Perissinotti AJ
    Ann Hematol; 2018 Apr; 97(4):573-584. PubMed ID: 29288428
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clofarabine, idarubicin, and cytarabine (CIA) as frontline therapy for patients ≤60 years with newly diagnosed acute myeloid leukemia.
    Nazha A; Kantarjian H; Ravandi F; Huang X; Choi S; Garcia-Manero G; Jabbour E; Borthakur G; Kadia T; Konopleva M; Cortes J; Ferrajoli A; Kornblau S; Daver N; Pemmaraju N; Andreeff M; Estrov Z; Du M; Brandt M; Faderl S
    Am J Hematol; 2013 Nov; 88(11):961-6. PubMed ID: 23877926
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The fludarabine, cytarabine, and granulocyte colony-stimulating factor (FLAG) chemotherapy regimen is an alternative to anthracycline-based therapy for the treatment of acute myeloid leukemia for patients with pre-existing cardiac disease.
    Saini L; Brandwein J; Turner R; Larratt L; Hamilton M; Peters A; Wu C; Zhu N; Patterson JM; Bolster L; Mant M; Ritchie B; Liew E; Ghosh S; Sandhu I
    Eur J Haematol; 2016 Nov; 97(5):471-478. PubMed ID: 27028202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. G-CSF priming, clofarabine, and high dose cytarabine (GCLAC) for upfront treatment of acute myeloid leukemia, advanced myelodysplastic syndrome or advanced myeloproliferative neoplasm.
    Becker PS; Medeiros BC; Stein AS; Othus M; Appelbaum FR; Forman SJ; Scott BL; Hendrie PC; Gardner KM; Pagel JM; Walter RB; Parks C; Wood BL; Abkowitz JL; Estey EH
    Am J Hematol; 2015 Apr; 90(4):295-300. PubMed ID: 25545153
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clofarabine in the treatment of elderly patients with acute myeloid leukemia.
    Aleem A; Anjum F; Algahtani F; Iqbal Z; Alsaleh K; Almomen A
    Asian Pac J Cancer Prev; 2013; 14(2):1089-92. PubMed ID: 23621192
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized phase 2 study of idarubicin and cytarabine with clofarabine or fludarabine in patients with newly diagnosed acute myeloid leukemia.
    Jabbour E; Short NJ; Ravandi F; Huang X; Xiao L; Garcia-Manero G; Plunkett W; Gandhi V; Sasaki K; Pemmaraju N; Daver NG; Borthakur G; Jain N; Konopleva M; Estrov Z; Kadia TM; Wierda WG; DiNardo CD; Brandt M; O'Brien SM; Cortes JE; Kantarjian H
    Cancer; 2017 Nov; 123(22):4430-4439. PubMed ID: 28708931
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.
    Estey E; Thall P; Andreeff M; Beran M; Kantarjian H; O'Brien S; Escudier S; Robertson LE; Koller C; Kornblau S
    J Clin Oncol; 1994 Apr; 12(4):671-8. PubMed ID: 7512125
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fludarabine, cytarabine, granulocyte colony-stimulating factor, and idarubicin (FLAG-IDA) for the treatment of children with poor-prognosis acute leukemia: the Hacettepe experience.
    Tavil B; Aytac S; Balci YI; Unal S; Kuskonmaz B; Yetgin S; Gurgey A; Tuncer M; Gumruk F; Uckan D; Cetin M
    Pediatr Hematol Oncol; 2010 Oct; 27(7):517-28. PubMed ID: 20677923
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
    Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
    Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
    Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
    Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cost of de novo acute myeloid leukemia induction therapy in adults: analysis of EORTC-GIMEMA AML10 and FLANG regimens.
    Clavio M; Quintino S; Masoudi B; Carrara S; Cerri R; Pierri I; Canepa L; Miglino M; Muner P; Damasio E; Gobbi M
    J Exp Clin Cancer Res; 2001 Jun; 20(2):165-73. PubMed ID: 11484970
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy of CLARA in recurrent/refractory acute myeloid leukaemia patients unresponsive to FLAG chemotherapy.
    Kaya AH; Tekgündüz E; Ilkkiliç K; Dal MS; Merdin A; Karakus A; Hacioglu SK; Bekdemir F; Çakar MK; Dogu MH; Ayyildiz MO; Korkmaz S; Altuntaş F;
    J Chemother; 2018 Feb; 30(1):44-48. PubMed ID: 29098953
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
    Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
    Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clofarabine Plus Low-Dose Cytarabine Is as Effective as and Less Toxic Than Intensive Chemotherapy in Elderly AML Patients.
    Takahashi K; Kantarjian H; Garcia-Manero G; Borthakur G; Kadia T; DiNardo C; Jabbour E; Pierce S; Estrov Z; Konopleva M; Andreeff M; Ravandi F; Cortes J
    Clin Lymphoma Myeloma Leuk; 2016 Mar; 16(3):163-8.e1-2. PubMed ID: 26752456
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [IDA-FLAG (idarubicin, fludarabine, high dosage cytarabine and G-CSF)--an effective therapy regimen in treatment of recurrent acute myelocytic leukemia in children and adolescents. Initial results of a pilot study].
    Fleischhack G; Graf N; Hasan C; Ackermann M; Breu H; Zernikow B; Bode U
    Klin Padiatr; 1996; 208(4):229-35. PubMed ID: 8926688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.
    Löwenberg B; Pabst T; Maertens J; van Norden Y; Biemond BJ; Schouten HC; Spertini O; Vellenga E; Graux C; Havelange V; de Greef GE; de Weerdt O; Legdeur MJ; Kuball J; Kooy MV; Gjertsen BT; Jongen-Lavrencic M; van de Loosdrecht AA; van Lammeren-Venema D; Hodossy B; Breems DA; Chalandon Y; Passweg J; Valk PJ; Manz MG; Ossenkoppele GJ;
    Blood; 2017 Mar; 129(12):1636-1645. PubMed ID: 28049642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retrospective Analysis of Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia Treated with FLAG at a Comprehensive Cancer Center.
    Tenold ME; Moskoff BN; Krishnan R; Rosenberg AS; Hoeg RT; Abedi M; Tuscano JM; Jonas BA
    Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e611-e618. PubMed ID: 33811007
    [TBL] [Abstract][Full Text] [Related]  

  • 18. FLAG salvage therapy combined with idarubicin in relapsed/refractory acute myeloid leukemia.
    Westhus J; Noppeney R; Dührsen U; Hanoun M
    Leuk Lymphoma; 2019 Apr; 60(4):1014-1022. PubMed ID: 30277107
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A prospective, multicenter phase II study of continuous infusion of FLAG for patients older than 60 yr with resistant acute myeloid leukemia: a comparison with intensive younger patients' trial.
    Kim H; Lee JH; Joo YD; Bae SH; Lee JH; Kim DY; Lee WS; Ryoo HM; Jo JC; Choi Y; Lee KH;
    Eur J Haematol; 2016 Feb; 96(2):188-97. PubMed ID: 25891993
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Effects of FLAG protocol in treatment of the first time induced non-remission acute myeloid leukemia].
    Wang SH; Yu L; Wang QS; Li HH; Zhao Y; Li F
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2007 Dec; 15(6):1297-9. PubMed ID: 18088488
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.